Research
Hormonal
Weekly subcutaneous tirzepatide (10-15 mg) produces greater weight loss (approx. 20-21%) than semaglutide in patients with obesity, with or without type 2 diabetes.
If you have obesity, weekly tirzepatide injections (10-15 mg) can help you lose about 20% of your body weight, which is more than semaglutide. This treatment is safe and effective for long-term use.
StrongSupportsVERY_HIGH confidence
Tirzepatide 15 mg vs. 10 mg vs. 5 mg vs. placebo... -20.9 vs. -19.5 vs. -15.0 vs. -3.1... Tirzepatide is a dual GIP and GLP-1 receptor agonist.
Why this rating
Based on multiple large-scale Phase 3 trials (SURMOUNT 1-4).
Source
Recent Progression of Incretin-Based Obesity Treatment
Dughyun Choi · Korean Journal of Medicine · 2024
DOI 10.3904/kjm.2024.99.2.78
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →